Heart burn: can zapping heart tissue stop deadly rhythms in brugada syndrome?
NCT ID NCT05685134
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a procedure called radiofrequency catheter ablation in 20 people with Brugada syndrome, a heart condition that can cause dangerous heart rhythms. Half received the real ablation, which uses heat to destroy small areas of heart tissue thought to cause the problem, while the other half received a sham procedure. The goal was to see if the ablation could normalize the heart's electrical pattern and prevent life-threatening arrhythmias over one year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- radiofrequency catheter ablation
- What this could lead to
- If successful, this procedure could reduce the risk of dangerous heart rhythms and potentially decrease the need for an implantable defibrillator in Brugada syndrome patients.
- What could go wrong
- This is a very small, early-stage trial with only 20 participants. The procedure involves burning heart tissue and carries risks like bleeding, infection, or heart damage. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Nov 2020
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a type 1 Brugada ECG pattern, as characterized by ST-segment elevation (≥2mm) with upward concavity associated with T-wave inversion, in at least one of the right precordial leads, positioned at the second, third or fourth intercostal space, either spontaneously or induced by a provocative test with Class I anti-arrhythmic drugs according to Vaughan Williams * Patients clinically stable for at least six months before the enrollment * Able to cope with follow-up visits up to one year after the intervention * Patients who have signed the written informed consent Exclusion Criteria: * Pregnant women * Patients with structural heart disease * Patients with a known cardiac or systemic autonomic disorder * Patients with a history of previous right ventricular outflow tract ablation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brugada syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto do Coração - InCor - HC/FMUSP
São Paulo, São Paulo, 05403-000, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.